ACADIA PHARMACEUTICALS INC(NASDAQ:ACAD) stock News

ACAD Latest News, Press Relases and Analysis

All

Press Releases

9 days ago - By: Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup

19 days ago - By: Chartmill

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity

2 days ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

4 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

9 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

14 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

16 days ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

17 days ago - By: Zacks Investment Research - Mentions: JAZZ AXSM

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

18 days ago - By: Benzinga

Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock

24 days ago - By: Investor's Business Daily - Mentions: RY RY.CA SLNO

Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges

24 days ago - By: Stocktwits - Mentions: AOR AVSU

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study

24 days ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

a month ago - By: Acadia Pharmaceuticals Inc.

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

a month ago - By: Benzinga

Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts

a month ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: JAZZ AXSM

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

2 months ago - By: Yahoo Finance - Mentions: GMAB

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

2 months ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

2 months ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

2 months ago - By: Zacks Investment Research - Mentions: GSK JAZZ

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

2 months ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Zacks Investment Research - Mentions: CRMD ARVN IMCR

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

2 months ago - By: The Motley Fool

Acadia (ACAD) Q2 Revenue Rises 9%

2 months ago - By: Zacks Investment Research - Mentions: NUVB

Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates

2 months ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

2 months ago - By: Zacks Investment Research - Mentions: ADPT

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

2 months ago - By: Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

2 months ago - By: Zacks Investment Research - Mentions: CPRX DNLI

Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?

2 months ago - By: Acadia Pharmaceuticals Inc.

ACADIA PHARMACEUTICALS INC (ACAD) Stock News

ACAD Latest News, Press Relases and Analysis

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock

Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

Acadia (ACAD) Q2 Revenue Rises 9%

Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer